WebOct 1, 2024 · Ondansetron Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Ondansetron Injection is approved for patients aged 6 months and older. Prevention of Postoperative Nausea and/or Vomiting WebHYDROXYZINE HYDROCHLORIDE tablet, film coated. NDC Code (s): 51655-467-52. Packager: Northwind Pharmaceuticals, LLC. This is a repackaged label. Source NDC Code (s): 0093-5062. Category: HUMAN PRESCRIPTION DRUG LABEL. DEA Schedule: None. Marketing Status: Abbreviated New Drug Application.
Ondansetron Uses, Dosage & Side Effects - Drugs.com
WebAug 5, 2024 · The more common side effects of ondansetron can include: headache. diarrhea. constipation. dizziness. drowsiness. If these effects are mild, they may go away … WebOndansetron orally disintegrating tablets are a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2. nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. devonshire mews n13
DailyMed - ONDANSETRON tablet, film coated
WebFDA label information for this drug is available at DailyMed. Use in Cancer Ondansetron hydrochloride is approved to prevent: Nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. It is used in adults and children. Ondansetron hydrochloride is also being studied in the treatment of other conditions. WebJan 19, 2024 · In patients where nausea and/or vomiting must be avoided postoperatively, ondansetron orally disintegrating tablets, USP are recommended even where the incidence of postoperative nausea and/or vomiting is low. ... For more information please see the prescribing information on DailyMed. Product Information; Product Name: Ondansetron … WebZOFRAN (ondansetron hydrochloride) tablets, for oral use ZOFRAN ODT (ondansetron) orally disintegrating tablets ZOFRAN (ondansetron hydrochloride) oral solution Initial U.S. Approval: 1991 . INDICATIONS AND USAGE ZOFRAN is a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with highly emetogenic … churchill\u0027s market